ReviewInternational journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases2020
Population-based seroprevalence surveys of anti-SARS-CoV-2 antibody: An up-to-date review.
Review in International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 134 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Fifth Medical Center of Chinese PLA General Hospital
Beijing 302 Hospital
Who cites it
134 citing papers in PubMed, 2 syntheses or guidelines pooled it, 224 citations in OpenAlex.
- Seroprevalence of anti-SARS-CoV-2 antibodies in Africa: A systematic review and meta-analysis.Reviews in medical virology · 2022Pooled it
- Seroprevalence of IgG antibodies against SARS-CoV-2 in India, March 2020 to August 2021: a systematic review and meta-analysis.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2022Pooled it
- Trial
- Article
- Serological responses to SARS-CoV-2 in urban and rural Ghana: Antibody waning and implications for long-term population immunity.PloS one · 2026Article
- Validation of polyester nasal swabs for post-mortem SARS-CoV-2 diagnosis in Karachi, Pakistan: a prospective surveillance analysis.Journal of global health · 2025Observational
- Seroprevalence of SARS-CoV-2 antibodies in Ethiopia: findings from the 2022 national population-based survey (second round).BMC infectious diseases · 2025Article
- Three-year Seroprevalence of SARS-CoV-2 Nucleocapsid Protein Antibody Among Children, Parental Awareness, and Contributors of Infection: A Single-school Cohort Study in Chiba, Japan.Journal of epidemiology · 2025Article
- Sero-prevalence of SARS-CoV-2 antibodies in Ethiopia: Results of the National Population Based Survey, 2021.PloS one · 2025Article
- Social inequalities in SARS-CoV-2 infection in high income countries: highlighting the need for an intersectional perspective in quantitative research.Frontiers in public health · 2025Review
- Age-dependent ACE2/TMPRSS2 expression and SARS-CoV-2 household transmission in Gran Canaria.PloS one · 2025Observational
- Quantitative SARS-CoV-2 Spike Receptor-Binding Domain and Neutralizing Antibody Titers in Previously Infected Persons, United States, January 2021-February 2022.Emerging infectious diseases · 2024Article
- Differences in SARS-COV-2 seroprevalence in the population of Cusco, Peru.Global epidemiology · 2024Article
- Seroprevalence of SARS-CoV-2 in 10 Regional Capitals of Cameroon, October-December 2020.Influenza and other respiratory viruses · 2024Article
- Article
- Seroepidemiology of SARS-CoV-2 in a cohort of pregnant women and their infants in Uganda and Malawi.PloS one · 2024Article
- Serological survey in a university community after the fourth wave of COVID-19 in Senegal.PloS one · 2024Article
- Observational
- Applications of time series analysis in epidemiology: Literature review and our experience during COVID-19 pandemic.World journal of clinical cases · 2023Review
- Measuring the clustering effect of the SARS-CoV-2 transmission in a school population: a cross-sectional study in a high incidence region.Scientific reports · 2023Article
74 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), has led to a global pandemic. However, the majority of currently available data are restricted to laboratory-confirmed cases for symptomatic patients, and the SARS-CoV-2 infection can manifest as an asymptomatic or mild disease. Therefore, the true extent of the burden of COVID-19 may be underestimated. Improved serological detection of specific antibodies against SARS-CoV-2 could help estimate the true numbers of infections. This article comprehensively reviews the associated literature and provides updated information regarding the seroprevalence of the anti-SARS-CoV-2 antibody. The seroprevalence can vary across different sites and the seroprevalence can increase with time during longitudinal follow-up. Although healthcare workers (HCWs), especially those caring for COVID-19 patients, are considered as a high-risk group, the seroprevalence in HCWs wearing adequate personal protective equipment is thought to be no higher than that in other groups. With regard to sex, no statistically significant difference has been found between male and female subjects. Some, but not all, studies have shown that children have a lower risk than other age groups. Finally, seroprevalence can vary according to different populations, such as pregnant women and hemodialysis patients; however, limited studies have examined these associations. Furthermore, the continued surveillance of seroprevalence is warranted to estimate and monitor the growing burden of COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.